Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapeutic strategy for familial amyloid polyneuropathy (FAP)].

Rinsho shinkeigaku = Clinical neurology - 1 Nov 2009

Ikeda Shu-ichi

Abstract excerpt

Familial amyloid polyneuropathy (FAP) was long considered to be an incurable disease, but a new therapeutic approach was developed 15 years ago. As the liver produces most of the transthyretin (TTR) in serum, it was assumed that the replacement of a liver expressing an abnormal TTR gene should stop the production of the variant TTR, the serum amyloid precursor in FAP. Until now about 1,500 FAP patients underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Amyloid
Share to Amyloid Neuropathies, Familial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Anti-Inflammatory Agents, Non-Steroidal

Share to Clinical Trials as Topic

Share to Liver Transplantation

Share to Prealbumin

Source

Identifiers

PMID: 20030258
DOI: 10.5692/clinicalneurol.49.953

Genes

FAP
TTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapeutic strategy for familial amyloid polyneuropathy (FAP)].PMID 20030258Read ↗

[Treatment of familial amyloid polyneuropathy].Semantic proximity Read ↗

[Analyses of amyloid formation mechanism in familial amyloidotic polyneuropathy and therapeutic trial].Semantic proximity Read ↗

Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP)Semantic proximity Read ↗

[Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].Semantic proximity Read ↗

[Hereditary transthyretin amyloidosis].Semantic proximity Read ↗

TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathiesSemantic proximity Read ↗

Familial amyloidotic polyneuropathy and transthyretin.Semantic proximity Read ↗

FAP neuropathy and emerging treatments.Semantic proximity Read ↗

[Familial amyloidotic polyneuropathy (FAP) type I and the therapies].Semantic proximity Read ↗

Current and future treatment of amyloid neuropathies.Semantic proximity Read ↗

Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients.Semantic proximity Read ↗

[Familial amyloidotic polyneuropathy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.